Abstract: Techniques to facilitate the creation of contracts and to automatically instantiate entitlements into contracts. A number of entitlement templates may be created for various entitlements. Each entitlement template is typically defined to include certain specifically defined entitlements. The entitlement templates may further be associated with products. A contract may thereafter be formed having any number of line items for one or more products and/or assets. Upon execution of the contract, an agreement is formed and the entitlements (if any) for each product/asset included in the contract may be instantiated (e.g., via a button on a screen). Upon instantiation of the entitlements into the contract, the covered products/assets become entitled and can thereafter receive the entitlements defined in the templates associated with the products/assets.

Abstract: Techniques to facilitate assignment and scheduling of activities. In accordance with a method, a chart showing a calendar of schedule for a number of available resources is provided in a first frame (or window) in a user interface menu, and a number of objects representative of a number of unplanned activities are provided in a second frame. A selection for an unplanned activity in the second frame (or a planned activity in the first frame) is received and, in response, selected ones of a number of objects in the chart are highlighted based on the selected activity. A request to assign the selected activity to a selected resource and to schedule the selected activity for a particular time duration is thereafter received. The requested assignment and scheduling may be accepted or rejected based on the requirements of the selected activity and the capabilities of the selected resource.

Abstract: There is provided a compound of Formula III or Formula IV wherein A is selected from H, OH, halogen and hydrocarbyl D, E and F are each independently of each other an optional linker group; P, Q and R are independently of each other a ring system, wherein R4 and R5 are independently selected from H, alkyl, cycloalkyl, alkenyl, acyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

Abstract: Techniques to schedule activities. In one method, a request to book an appointment for an activity in a particular schedule is initially received. In response, time slots available in the schedule for booking the activity are determined, and a set (all or a subset) of the time slots is provided as possible appointment choices. The time slots in the set are temporarily locked. A next set of time slots or more time slots may be requested (if the time slots provided are not acceptable or desirable), in which case additional time slots may be provided. Thereafter, a selection for one of the time slots is received. In response, the activity is booked in the selected time slot and previously locked time slots are released. The locked time slots may also be released if no selection is received after a particular amount of time.

Abstract: A compound having Formula I R1—Z—R2Formula I wherein R1 is an optionally substituted phenyl ring; R2 is or comprises an optionally substituted aromatic ring; and Z is —X—Y—L— or —Y—X—L— wherein either X is selected from —S(?O)(?O)— and —C(?O)—; and Y is —NR3—; or X is selected from —S(?O)(?O)— and —S—, and Y is —C(R4)(R5)—; L is an optional linker; and R3, R4 and R5 are each independently selected from H and hydrocarbyl; and wherein when R2 comprises the following structural moiety wherein Q is an atom selected from the group consisting of S, O, N and C; the compound is selected from compounds of the formulae R1—C(?O)—NR3—L—R2; R1—S(?O)(?O)—C(R4)(R5)—L—R2; R1—S—C(R4)(R5)—L—R2; R1—NR3—S(?O)(?O)—L—R2; R1—NR3—C(?O)—L—R2; R1—C(R4)(R5)—S(?O)(?O)—L—R2; and R1—C(R4)(R5)—S—L—R2.

Abstract: There is provided a compound of Formula I wherein X, Y and Z are each independently of each other an optional linker group; R1 is a ring system; R2 is selected from hydrocarbyl groups, oxyhydrocarbyl groups, cyano (—CN), nitro (—NO2) and halogens; R3 and R4 are independently selected from H and hydrocarbyl, ring A and B are independently optionally further substituted.

Abstract: There is provided a compound of Formula I wherein X is a ring system; R1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; R2 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein when X is a steroidal structure and both of R1 and R2 are sulphamate groups, the steroidal ring system (X) represents an oestrogen; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.

Abstract: There is provided a compound of Formula I wherein X is a ring system; R1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; R2 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein when X is a steroidal structure and both of R1 and R2 are sulphamate groups, the steroidal ring system (X) represents an oestrogen; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.

Abstract: There is provided a compound of Formula I wherein each T is independently selected from H, hydrocarbyl, —F—R, and a bond with one of D, E, P or Q, or together with one of P and Q forms a ring; Z is a suitable atom the valency of which is m; D, E and F are each independently of each other an optional linker group, wherein when Z is nitrogen E is other than CH2 and C?O; P, Q and R are independently of each other a ring system; and at least Q comprises a sulphamate group.

Abstract: There is provided a compound of Formula I wherein each T is independently selected from H, hydrocarbyl, —F—R, and a bond with one of D, E, P or Q, or together with one of P and Q forms a ring; Z is a suitable atom the valency of which is m; D, E and F are each independently of each other an optional linker group, wherein when Z is nitrogen E is other than CH2 and C?O; P, Q and R are independently of each other a ring system; and at least Q comprises a sulphamate group.

Abstract: A compound having Formula I R1-Z-R2??Formula I wherein R1 is an optionally substituted phenyl ring; R2 is or comprises an optionally substituted-aromatic ring; and Z is -X-Y-L- or -Y-X-L- wherein either X is selected from —S(?O)(?O)— and —C(?O)—, and Y is —NR3—; or X is selected from —S(?O)(?O)— and —S—, and Y is —C(R4)(R5)—; L is an optional linker; and R3, R4 and R5 are each independently selected from H and hydrocarbyl; and wherein when R2 comprises the following structural moiety wherein Q is an atom selected from the group consisting of S, O, N and C; the compound is selected from compounds of the formulae R1C(?O)—NR3-L-R2; R1—S(?O)(?O)—C(R4)(R5)-L-R2; R1—S—C(R4)(R5)-L-R2; R1—NR3—S(?O)(?O)-L-R2; R1—NR3—C(?O)-L-R2; R1—C(R4)(R5)—S(?O)(?O)-L-R2; and R1—C(R4)(R5)—S-L-R2.

Abstract: A compound is described. The compound has the formula (Ia) as presented in the FIG. 1; wherein: X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group. The compound is capable of inhibiting steroid sulphatase (STS) activity.

Abstract: The present invention provides use of a compound in the manufacture of a medicament to inhibit 11&bgr;-HSD activity, wherein the compound is selected from glycyrrhetinic acid derivatives, progesterone and progesterone derivatives.

Abstract: A compound having Formula I 1

Abstract: There is provided a compound of Formula I 1

Abstract: There is provided a compound of Formula I 1

Abstract: A compound is described. The compound has the formula (Ia) as presented in the FIG. 1; wherein: X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group. The compound is capable of inhibiting steroid sulphatase (STS) activity.

Abstract: A system comprising a IL-6-IL-6sR complex and an agent that can block the interaction of the complex with gp130 to regulate oestrogen synthesis.

Abstract: An assay comprising determining the absence or presence of steroid sulphatase activity is described. In a preferred embodiment, the assay uses white blood cells. The assay can be used to determine if an agent is an in vitro and/or in vivo steroid sulphatase inhibitor.